Drug Profile
Ice 3682
Alternative Names: Ice-3682; JNJ 42503682Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Janssen Pharmaceuticals
- Developer Ice Therapeutics
- Class Analgesics; Small molecules
- Mechanism of Action TRPM8 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Neuropathic-pain in Israel (PO)
- 04 Jul 2017 Ice Therapeutics in-licenses Ice 3682 from Janssen Pharmaceuticals before July 2017 (FutuRx website, July 2017)